<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288417</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 10.05</org_study_id>
    <nct_id>NCT01288417</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir</brief_title>
  <acronym>OPAL</acronym>
  <official_title>Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of boceprevir (steady state) on the&#xD;
      pharmacokinetics of a single dose of raltegravir. The effect on the boceprevir&#xD;
      pharmacokinetics of a single dose raltegravir will also be evaluated (compared to historical&#xD;
      controls). Furthermore, the safety profile of the combination is studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A considerable percentage of HIV infected patients is also infected with the hepatitis C&#xD;
      virus (HCV). HIV/HCV co-infected patients are likely to simultaneously use treatment for&#xD;
      their HIV infection as well as HCV treatment. Therefore, it is important to know if drug-drug&#xD;
      interactions occur when combining those treatments.&#xD;
&#xD;
      Raltegravir is an HIV integrase inhibitor and approved by the FDA in 2007. Boceprevir is a&#xD;
      potent HCV NS3 serine protease inhibitor and is currently in Phase III clinical development.&#xD;
&#xD;
      Combined use of boceprevir and raltegravir is not expected to give a major drug-drug&#xD;
      interaction as raltegravir is not a CYP3A substrate and thus will not be affected by the&#xD;
      strong inhibition of CYP3A by boceprevir. Raltegravir is metabolized by UGT but boceprevir is&#xD;
      not known to influence UGT. However, recent data indicate that raltegravir is a P-gp&#xD;
      substrate and boceprevir is a substrate and a moderate inhibitor of P-gp in vitro.&#xD;
&#xD;
      Even when no drug interaction is expected, it may be recommended to collect sufficient&#xD;
      evidence that this is the case as in many cases un-expected drug-drug interactions have been&#xD;
      observed in the past.&#xD;
&#xD;
      The current study is designed to evaluate the effect of steady state boceprevir on the&#xD;
      pharmacokinetics of a single dose of raltegravir and the safety profile when used in&#xD;
      combination. Furthermore the effect of a single dose raltegravir is studied on the&#xD;
      pharmacokinetics of steady state boceprevir in comparison with historical controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>raltegravir concentrations</measure>
    <time_frame>during 12hours on two occasions</time_frame>
    <description>To determine the effect of chronic use of boceprevir on the single-dose pharmacokinetics of raltegravir 400mg in healthy volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>entire study</time_frame>
    <description>to determine the safety of a single dose of raltegravir 400mg when combined with chronic use of boceprevir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>boceprevir concentrations</measure>
    <time_frame>during 8 hours on one occasion; predose 4 times over a period of 10 days</time_frame>
    <description>To determine the effect of a single-dose pharmacokinetics of raltegravir 400mg on chronic use of boceprevir in healthy volunteers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infections</condition>
  <condition>HCV Infections</condition>
  <arm_group>
    <arm_group_label>boceprevir + raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 days of boceprevir 800mg TID; day 10 two doses of boceprevir 800mg and one dose of raltegravir 400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>raltegravir alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of raltegravir 400mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>boceprevir</intervention_name>
    <description>10 days of boceprevir 800mg TID</description>
    <arm_group_label>boceprevir + raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>raltegravir 400mg single dose</description>
    <arm_group_label>boceprevir + raltegravir</arm_group_label>
    <arm_group_label>raltegravir alone</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is at least 18 and not older than 55 years at scree-ning.&#xD;
&#xD;
          -  Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at&#xD;
             least 3 months prior to the first dosing&#xD;
&#xD;
          -  Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, electrocardiography, results of biochemistry, haematology and&#xD;
             urinalysis testing within 4 weeks prior to Day 1. Results of biochemistry, haematology&#xD;
             and urinalysis testing should be within the laboratory's reference ranges. If&#xD;
             laboratory results are not within the reference ranges, the subject is included on&#xD;
             condition that the Investigator judges that the deviations are not clinically&#xD;
             relevant. This should be clearly recorded.&#xD;
&#xD;
          -  Subject has a normal blood pressure and pulse rate, according to the Investigator's&#xD;
             judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.&#xD;
&#xD;
          -  Positive HIV test.&#xD;
&#xD;
          -  Positive hepatitis B or C test.&#xD;
&#xD;
          -  Pregnant female (as confirmed by an HCG test performed less than 4 weeks before Day 1)&#xD;
             or breast-feeding female. Female subjects of childbearing potential without adequate&#xD;
             contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal)&#xD;
             intrauterine device, total abstinence, double barrier methods, or two years&#xD;
             post-menopausal. They must agree to take precautions in order to prevent a pregnancy&#xD;
             throughout the entire conduct of the trial.&#xD;
&#xD;
          -  Therapy with any drug (for two weeks preceding dosing), ex-cept for paracetamol.&#xD;
&#xD;
          -  Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular&#xD;
             disorders, neurological disorders (especially seizures and migraine), psychiatric&#xD;
             disorders, gastro-intestinal disorders, renal and hepatic disorders, hormonal&#xD;
             disorders (especially diabetes mellitus), coagulation disorders.&#xD;
&#xD;
          -  Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          -  History of or current abuse of drugs, alcohol or solvents.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the trial and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Participation in a drug trial within 60 days prior to the first dose.&#xD;
&#xD;
          -  Donation of blood within 60 days prior to the first dose.&#xD;
&#xD;
          -  Febrile illness within 3 days before the first dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Burger, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRCN</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://retroconference.org/2012b/Abstracts/45378.htm</url>
    <description>abstract with results of the study, presented at CROI 2012</description>
  </link>
  <results_reference>
    <citation>de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2013 Jan;56(2):300-6. doi: 10.1093/cid/cis824. Epub 2012 Sep 21.</citation>
    <PMID>23001704</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infections</keyword>
  <keyword>HCV infections</keyword>
  <keyword>interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>raltegravir</keyword>
  <keyword>boceprevir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

